Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to Chemotherapy

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Du, Wei ^a   Yi, Yong ^b   Zhang, Haibo ^b   Bergholz, Johann ^a,b   Wu, Junfeng ^a   Ying, Haoqiang ^c   Zhang, Yujun ^b   Xiao, Zhi Xiong Jim ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MDM2; RAPAMYCIN; SOMATOMEDIN C; ANTINEOPLASTIC ANTIBIOTIC; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MURINE DOUBLE MINUTE 2 GENE; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; STEADY STATE; TUMOR GENE; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

EUKARYOTA; MURINAE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84876995212     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063179     Document Type: Article

References (44)

1. Bond GL, Hu W, Levine AJ, (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8.
2. Momand J, Jung D, Wilczynski S, Niland J, (1998) The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459.
3. Ganguli G, Wasylyk B, (2003) p53-independent functions of MDM2. Mol Cancer Res 1: 1027-1035.
4. Bouska A, Eischen CM (2009) Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci.
5. Xiao ZX, Chen J, Levine A, Modjtahedi N, Xing J, et al. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
6. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S, et al. (1999) RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3: 181-193.
7. Gu L, Ying H, Zheng H, Murray SA, Xiao ZX, (2003) The MDM2 RING finger is required for cell cycle-dependent regulation of its protein expression. FEBS Lett 544: 218-222.
8. Sdek P, Ying H, Zheng H, Margulis A, Tang X, et al. (2004) The central acidic domain of MDM2 is critical in inhibition of retinoblastoma protein-mediated suppression of E2F and cell growth. J Biol Chem 279: 53317-53322.
9. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, et al. (2005) MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699-708.
10. Dobbelstein M, Wienzek S, Konig C, Roth J, (1999) Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18: 2101-2106.
11. Zeng X, Chen L, Jost CA, Maya R, Keller D, et al. (1999) MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19: 3257-3266.
12. Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, et al. (2005) Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 24: 7238-7247.
13. Jin Y, Lee H, Zeng SX, Dai MS, Lu H, (2003) MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. Embo J 22: 6365-6377.
14. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ, (2001) Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294: 1307-1313.
15. Salcedo A, Mayor F Jr, Penela P, (2006) Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. Embo J 25: 4752-4762.
16. Mayo LD, Donner DB, (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98: 11598-11603.
17. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, et al. (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982.
18. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, et al. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 28: 28.
19. Feng J, Tamaskovic R, Yang Z, Brazil DP, Merlo A, et al. (2004) Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem.
20. Bjornsti MA, Houghton PJ, (2004) Lost in translation; Dysregulation of cap-dependent translation and cancer. Cancer Cell 5: 519-523.
21. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, et al. (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98: 10314-10319.
22. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
23. Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng XD, et al. (2006) Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10: 269-280.
24. Murray SA, Zheng H, Gu L, Xiao ZX, (2003) IGF-1 activates p21 to inhibit UV-induced cell death. Oncogene 22: 1703-1711.
25. Du W, Wu J, Walsh EM, Zhang Y, Chen CY, et al. (2009) Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3. J Biol Chem 284: 26315-26321.
26. Vlahos CJ, Matter WF, Hui KY, Brown RF, (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
27. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, et al. (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229-233.
28. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH, (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78: 35-43.
29. Gingras AC, Raught B, Sonenberg N, (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826.
30. Mothe-Satney I, Yang D, Fadden P, Haystead TA, Lawrence JC Jr, (2000) Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol Cell Biol 20: 3558-3567.
31. Wu G, Xing M, Mambo E, Huang X, Liu J, et al. (2005) Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7: R609-616.
32. Landers JE, Haines DS, Strauss JFI, George DL, (1994) Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750.
33. Landers JE, Cassel SL, George DL, (1997) Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57: 3562-3568.
34. Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, et al. (2003) BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 3: 145-160.
35. Xiong L, Kou F, Yang Y, Wu J, (2007) A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop. J Cell Biol 178: 995-1007.
36. Moumen A, Patane S, Porras A, Dono R, Maina F, (2007) Met acts on Mdm2 via mTOR to signal cell survival during development. Development 134: 1443-1451.
37. Bjornsti MA, Houghton PJ, (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348.
38. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ, (2006) CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8: 394-401.
39. Mills RE, Taylor KR, Podshivalova K, McKay DB, Jameson JM, (2008) Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice. J Immunol 181: 3974-3983.
40. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, et al. (1995) Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55: 1982-1988.
41. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, et al. (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120: 747-759.
42. Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, et al. (2004) Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103: 3138-3147.
43. Yan H, Frost P, Shi Y, Hoang B, Sharma S, et al. (2006) Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 66: 2305-2313.
44. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, et al. (2008) Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 118: 2651-2660.